1. bookVolume 29 (2021): Edition 4 (October 2021)
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais
access type Accès libre

COVID-19 associated coagulopathy is correlated with increased age and markers of inflammation response

Publié en ligne: 22 Oct 2021
Volume & Edition: Volume 29 (2021) - Edition 4 (October 2021)
Pages: 387 - 394
Reçu: 03 Aug 2021
Accepté: 08 Oct 2021
Détails du magazine
License
Format
Magazine
eISSN
2284-5623
Première parution
08 Aug 2013
Périodicité
4 fois par an
Langues
Anglais
Abstract

Background: The severe manifestations of the coronavirus disease 2019 (COVID-19) are linked to viral hyper-inflammation, cytokine release syndrome and subsequent coagulation disturbances. The most common coagulation abnormality observed in COVID-19 patients is the elevation of the plasma levels of D-dimers. The aim of this study was to evaluate the characteristics of COVID-19-associated inflammatory syndrome and coagulopathy, in correlation with disease severity.

Methods: We performed a cross-sectional study, enrolling all consecutive COVID-19 patients treated in the Adulti 3 Department of the Prof. Dr. Matei Bals National Institute of Infectious Diseases, Bucharest, Romania, between 1st march and 30th September 2020. We recorded clinical and epidemiological characteristics, inflammatory markers, coagulation abnormalities and lymphocyte count. The severity of lung involvement was assessed using native Computed Tomography examination.

Results: We included 106 patients with SARS-COV2 infection, 50 males (47.2%) and 56 females (52.8%), age range 14-91 years. All markers of inflammation were increased in our study in patients with severe disease, as were lactate dehydrogenase, monocyte distribution width, and neutrophil-to-lymphocyte ratio. An elevated level of serum D-dimers was observed in approximately half of our subjects and was associated with disease severity. Our best linear regression model for predicting COVID-19 coagulopathy (manifested as abnormal D-dimer levels) included age, fibrinogen, and lymphocyte count.

Conclusion: Our findings emphasize the association between COVID-19 coagulopathy and the presence of systemic inflammation. A significant proportion of patients with moderate and severe disease had coagulation abnormalities and these were linked with the presence of inflammation and older age..

Keywords

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARSCoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar; 19(3):141-54. DOI: 10.1038/s41579-020-00459-710.1038/s41579-020-00459-7 Search in Google Scholar

2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020;323:1239-42. DOI: 10.1001/ jama.2020.264810.1001/jama.2020.2648 Search in Google Scholar

3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. DOI: 10.1016/S0140-6736(20)30628-010.1016/S0140-6736(20)30628-0 Search in Google Scholar

4. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010;38:S26-34. DOI: 10.1097/CCM. 0b013e3181c98d21 Search in Google Scholar

5. Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, et al. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021 Mar;46:100745. DOI: 10.1016/j.blre.2020.10074510.1016/j.blre.2020.100745 Search in Google Scholar

6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. DOI: 10.1016/S0140-6736(20)30566-310.1016/S0140-6736(20)30566-3 Search in Google Scholar

7. Teuwen L, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nature Rev Immunol. 2020;20:389-91. DOI: 10.1038/s41577-020-0343-010.1038/s41577-020-0343-0724024432439870 Search in Google Scholar

8. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18:1324-9. DOI: 10.1111/jth.1485910.1111/jth.14859726473032306492 Search in Google Scholar

9. Lee SG, Fralick M, Sholzberg M. Coagulopathy associated with COVID-19. CMAJ. 2020 May 25;192(21):E583. DOI: 10.1503/cmaj.20068510.1503/cmaj.200685725997032357997 Search in Google Scholar

10. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40. DOI: 10.1182/blood.202000600010.1182/blood.2020006000727382732339221 Search in Google Scholar

11. Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol. 2012 Jan;34(1):167-79. DOI: 10.1007/s00281-011-0283-710.1007/s00281-011-0283-7323366021805225 Search in Google Scholar

12. Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Hae-most. 1996 Nov;76(5):738-42. DOI: 10.1055/s-0038-165065310.1055/s-0038-1650653 Search in Google Scholar

13. Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998;79:74-8. DOI: 10.1055/s-0037-161422310.1055/s-0037-1614223 Search in Google Scholar

14. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001 Oct;115(1):3-1. DOI: 10.1046/j.1365-2141.2001.03061.x10.1046/j.1365-2141.2001.03061.x11722403 Search in Google Scholar

15. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020 Jun;46(6):1105-8. DOI: 10.1007/s00134-020-06059-610.1007/s00134-020-06059-6718653532347323 Search in Google Scholar

16. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-9. DOI: 10.1001/jama.2020.158510.1001/jama.2020.1585704288132031570 Search in Google Scholar

17. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020 May 20;18(1):206. DOI: 10.1186/ s12967-020-02374-010.1186/s12967-020-02374-0723788032434518 Search in Google Scholar

18. Muniyappa R, Gubbi S. COVID-19 pandemic, corona-viruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318:E736-E741. DOI: 10.1152/ajpendo.00124.202010.1152/ajpendo.00124.2020719163332228322 Search in Google Scholar

19. Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020 Sep 18;11(1):53. DOI: 10.1186/ s13293-020-00330-710.1186/s13293-020-00330-7749899732948238 Search in Google Scholar

20. Wong RS, Wu A, To KF, Lee N, Lam CWK, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326: 1358-62. DOI: 10.1136/ bmj.326.7403.135810.1136/bmj.326.7403.135816212412816821 Search in Google Scholar

21. Panesar, NS. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med Hypotheses 2008; 71: 298-301. DOI: 10.1016/j.mehy.2008.03.01910.1016/j.mehy.2008.03.019713135218448259 Search in Google Scholar

22. Yang M, Li CK, Li K, Hon KL, Ng MH, Chan PK, et al. Hematological findings in SARS patients and possible mechanisms (review). Int J Mol Med 2004;14:311-5. DOI: 10.3892/ijmm.14.2.31110.3892/ijmm.14.2.311 Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo